A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Phase of Trial: Phase III
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Rozanolixizumab (Primary)
- Indications Myasthenia gravis
- Focus Registrational; Therapeutic Use
- Acronyms MycarinGstudy
- Sponsors UCB
- 05 Jul 2019 Status changed from not yet recruiting to recruiting.
- 04 Jun 2019 Planned initiation date changed from 1 May 2019 to 1 Jun 2019.
- 29 May 2019 Status changed from planning to not yet recruiting.